anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To enable the efficient separation of an organogermanium compound and an inorganic germanium compound by applying a germanium-containing medicated plant to a specific combined column. SOLUTION: An extract from a germanium-containing medicated plant or its treatment product is applied to a combined column containing a cation exchange resin in the lower part of the column and an anion exchange resin in the upper part of the column. Thereby, an organogermanium compound in the extract is bonded to the upper part of the column. The combined column is eluted with deionized water and the resultant eluate is collected to thereby afford a solution containing only an inorganic germanium. The combined column is eluted with an alkaline solution to thereby release the organogermanium compound bonded to the upper part of the column and bond the organogermanium compound to the lower part of the column. The combined column is then eluted with deionized water to collect the eluate. Thereby, a solution containing only the organogermanium is obtained.
The DELFLEX® peritoneal dialysis solutions (low magnesium/low calcium) are sterile, non-pyrogenic formulations of dextrose and electrolytes in water for injection, USP, for use in peritoneal dialysis. These solutions do not contain antimicrobial agents or additional buffers. The stay•safe exchange set utilizes an easy to use dial designed to eliminate the use of clamps and to prevent touch contamination of internal connection components. Composition, calculated osmolarity, pH, and ionic concentrations are shown in Table 2. 

Dextrose, USP, is chemically designated D-glucose monohydrate (C 6H 12O 6•H 2O) a hexose sugar freely soluble in water. The structural formula is shown here: 

Calcium chloride, USP, is chemically designated calcium chloride dihydrate (CaCl 2•2H 2O) white fragments or granules freely soluble in water. 

Magnesium chloride, USP, is chemically designated magnesium chloride hexahydrate (MgCl 2•6H 2O) colorless flakes or crystals very soluble in water. 

Sodium lactate solution, USP, is chemically designated (CH 3CH(OH)COONa), a 60% aqueous solution miscible in water. 

Sodium chloride, USP, is chemically designated (NaCl), a white, crystalline compound freely soluble in water.

Water for injection, USP, is chemically designated (H 2O). 

Hydrochloric Acid or Sodium Hydroxide may be added for pH adjustment. pH is 5.5 ± 0.5.

Exposure to temperatures above 25°C (77°F) during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. Since the inner bag is compounded from a specific polyvinyl chloride, water may permeate from the inner bag into the overwrap in quantities insufficient to affect the solution significantly. Solutions in contact with the plastic inner bag can cause certain chemical components of the bag to leach out in very small amounts; however, the safety of the plastic formulation is supported by biological tests for plastic containers.
[Problem] To provide a novel adhesive molecule. [Solution] Provided is an adhesive molecule which has the amino acid sequence of SEQ. ID NO. 1, or an amino acid sequence obtained by including, in the sequence of SEQ. ID NO. 1, a conservative amino acid substitution, deletion, insertion, and/or modification.
The invention discloses a pure traditional Chinese medicine composition used for treating cancer, and a preparation method thereof. The composition provided by the invention comprises medicine materials of, by weight: 87 parts of tenacious condorvine root or herb, and 13 parts of stone-like omphalia. The cancer-treating medicine composition provided by the invention is a traditional Chinese medicine preparation. With the tablets provided by the invention, human body functions can be regulated, such that functions of cancer inhibiting, inflammation eliminating, asthma relieving, phlegm dissipating, and mass removing can be provided. The medicine composition is used in treatments of various cancers, and can also be used in auxiliary treatments of various cancers after radiotherapies, chemotherapies, and operations. The medicine composition provided by the invention is advantaged in small administration dosage, convenient administration, fast absorbance, high bioavailability, convenient carrying, accurate quantitation, stable quality, and the like. The medicine composition can be produced by using regular equipments.
Fractional CO2 laser system that utilizes a sealed off, all metal carbon dioxide gas tube that is Radio Frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The system has a programmable 2 axis scanning laser beam device that allows the physician to select the skin area coverage from a selection of predetermined patterns in different sizes based on the skin area to be treated. The versatility of the fractional CO2RE system enables precise, effective and simultaneous treatment of the skin's surface in the middle, and deep dermal levels.
At the beginning, the study design includes an familiarisation appointment with performance tests and training on the eccentric arm-crank device (KREHA). At least one week later, the first test sequence including a maximum strength test (bench press), magnetic resonance imaging (MRI) to determine the muscle cross-section area of the upper arm and a test to determine the anaerobic performance (Wingate test) is conducted. The second test sequence takes place one to three days later. This includes a handgrip strength test, an aerobic endurance test (ramp test on the arm crank ergometer with ergospirometry) and a further familiarisation training on the KREHA. The training phase starts within two weeks after the pre-tests have been completed. There are two to a maximum of three trainings per week. These take 30 to 60 minutes and take place on the KREHA device under the supervision of the study staff. The training phase lasts a maximum of twelve weeks (20 training sessions). The first test sequence is repeated five to eight days after the last workout. The second test sequence takes place at the same time interval as in the pre-tests.
Organometallic oestrogen complex corresponding to the formula (I): <IMAGE>  in which   . A represents a divalent residue of a C1 to C7 alkyl radical or a C2 to C7 alkenyl or alkynyl radical . Mx represents one or more transition metals which are identical or different, . L'y represents one or more ligands, which are identical or different, which complex the said metal(s) Mx, and   . L represents a ligand of Mx covalently coupled to A or . L represents "nothing", in which case MxL'y is directly grafted onto a carbon of a triple bond C IDENTICAL C of A which represents an alkynyl, . R represents H or a C1 to C7 alkyl or alkoxy optionally substituted by one or more halogens.
NEOD001 will be administered intravenously once every 28 days. The starting dose will be 0.5 mg/kg. Dose escalation will continue until the the maximum tolerated dose is determined for single agent NEOD001. Approximately 20 additional subjects will be treated with the maximum tolerated dose.
BACKGROUND: Sonographic placental elastography has recently been employed as a non-invasive tool to investigate the structural alterations associated with various conditions such as pre-eclampsia, gestational diabetes and fetal growth restriction (FGR). The study was conducted based on the hypothesis that the placental elasticity might differ with varying severity of FGR and with that of appropriate for gestational age (AGA) pregnancies.
METHODS: This study involved 121 pregnant women, with 54 in the normal group and 67 in the FGR group, which was defined as the fetal weight below the 10th percentile for gestational age. The FGR pregnancies were sub grouped into different stages based on the presence and extent of Doppler abnormalities. Shear-wave elastography was carried out to investigate the placental elasticity values, which were compared using the Kruskal-Wallis test. A P value of ≤0.05 was considered significant.
RESULTS: The placental elasticity differed significantly between pregnancies with and without FGR and among the different stages of FGR. There was a significant difference in PE (kPa) and SWV (m/s) among groups, with a p-value of 0.000001. PE and SWV in FGR pregnancies were significantly higher compared to AGA as a whole using t-test with p values of <0.0001. Doppler indices of umbilical, uterine and fetal middle cerebral arteries also correlated significantly with these.
CONCLUSION: The study suggests that placental elasticity values reflect structural alterations associated with FGR and could serve as a valuable tool in the early detection and staging of this condition.
There is no specific antidote for FANAPT. Therefore appropriate supportive measures should be instituted. In case of acute overdose, the physician should establish and maintain an airway and ensure adequate oxygenation and ventilation. Gastric lavage (after intubation, if patient is unconscious) and administration of activated charcoal together with a laxative should be considered. The possibility of obtundation, seizures or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis. Cardiovascular monitoring should commence immediately and should include continuous ECG monitoring to detect possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide and quinidine should not be used, as they have the potential for QT-prolonging effects that might be additive to those of FANAPT. Similarly, it is reasonable to expect that the alpha-blocking properties of bretylium might be additive to those of FANAPT, resulting in problematic hypotension. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of FANAPT-induced alpha blockade). In cases of severe extrapyramidal symptoms, anticholinergic medication should be administered. Close medical supervision should continue until the patient recovers.
Macrophages are crucial cells in the human body's innate immunity and are engaged in a variety of non-inflammatory reactions. Macrophages can develop into two kinds when stimulated by distinct internal environments: pro-inflammatory M1-like macrophages and anti-inflammatory M2-type macrophages. During inflammation, the two kinds of macrophages are activated alternatively, and maintaining a reasonably steady ratio is critical for maintaining homeostasis in vivo. M1 macrophages can induce inflammation, but M2 macrophages suppress it. The imbalance between the two kinds of macrophages will have a significant impact on the illness process. As a result, there are an increasing number of research being conducted on relieving or curing illnesses by altering the amount of macrophages. This review summarizes the role of macrophage polarization in various inflammatory diseases, including autoimmune diseases (RA, EAE, MS, AIH, IBD, CD), allergic diseases (allergic rhinitis, allergic dermatitis, allergic asthma), atherosclerosis, obesity and type 2 diabetes, metabolic homeostasis, and the compounds or drugs that have been discovered or applied to the treatment of these diseases by targeting macrophage polarization.
Polynucleotide sequence for novel G-protein coupled receptor LUSTR2 and uses thereof. The present invention is directed to a polynucleotide sequence of a novel G-Protein Coupled Receptor LUSTR2. More particularly, the present invention provides a polynucleotide sequence comprising the nucleic acid sequence SEQ ID NO: 1 or nucleic acid sequences that hybridize to SEQ ID NO: 1 or its complimentary strand having at least 40% sequence identity. Preferably, the hybridizing nucleic acid sequence should hybridize under stringent conditions and in particular have 85% sequence identity, more preferably 90% sequence identity, and most preferably 95% sequence identity. The invention also provides the human LUSTR2 associated with the haemaotological, peripheral and central nervous system, COPD, asthma, genito-urological, metabolic diseases and pancreas and heart disorders as a result of relative quantification of the mRNA distribution in different human tissues by expression profiling. The invention also provides assays for the identification of compounds useful for the modulation of hematological, peripheral and central nervous system, COPD, asthma, genito-urological, metabolic diseases and pancreas and heart disorders for treating or preventing hematological, peripheral and central nervous system, COPD, asthma, genito-urological, metabolic diseases and pancreas and heart disorders associated with expression of the LUSTR2. The methods of the invention involve cell-free and cell-based assays that identify compounds which bind to and/or activate or inhibit the activity of LUSTR2, a G protein coupled receptor, followed by an in vivo assay of the effect of the compound on hematological, peripheral and central nervous system, COPD, asthma, genito-urological, metabolic diseases and pancreas and heart disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of LUSTR2 as well as pharmaceutical compositions comprising such compounds.
After the research groups were formed, a six-session interview programme was created for the participants included in the experimental group . In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping, cognitive restructuring) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. Virtual reality-based intervention was effectively used as an important intervention tool in the implementation of the interventions and in the evaluation of the implemented interventions in four sessions of a total of six sessions. During the application, the participants were asked to evaluate their anxiety in the range of 0-10 as subjective feedback via the 'Amelia VR Platform', and ratings were requested every three minutes during the 15-minute experience of the virtual reality platform, especially at moments when their anxiety increased subjectively.
The main cause of death in lung cancer patients is metastasis. Thus, efforts to suppress micrometastasis or distant metastasis in lung cancer, identify therapeutic targets and develop related drugs are ongoing. In this study, we identified SET and MYND domain-containing protein 5 (SMYD5) as a novel metastasis regulator in lung cancer and found that SMYD5 was overexpressed in lung cancer based on both RNA-sequencing analysis results derived from the TCGA portal and immunohistochemical analysis results; knockdown of SMYD5 inhibited cell migration and invasion by changing epithelial-mesenchymal transition markers and MMP9 expression in NCI-H1299 and H1703 cell lines. Additionally, SMYD5 knockdown increased Src homology 2-b3 expression by decreasing the level of H4K20 trimethylation. Furthermore, in an in vitro epithelial-mesenchymal transition system using TGF-β treatment, SMYD5 knockdown resulted in reduced cell migration and invasion in the highly invasive NCI-H1299 and H1703 cell lines. Based on these findings, we propose that SMYD5 could serve as a potential therapeutic target for lung cancer treatment and that cotreatment with an SMYD5 inhibitor and chemotherapy may enhance the therapeutic effect of lung cancer treatment.
56 female volleyball players will randomized into 2 groups of 28 people each. In the evaluations conducted on the participants, rotational normal joint movements of the athletes will be measured using a digital inclinometer. The spike velocities of the athletes will be determined using a sports radar (Sports Radar 3300, Sports Electronics Inc, Washington, D.C. USA.). Participants will be randomly divided into two different groups consisting of 28 individuals each. The Proprioceptive Neuromuscular Facilitation Stretching Group (PNFG) participants will undergo one session of PNF posterior shoulder stretching exercise in the modified sleeper position. The Percussive Massage Treatment Group (PMTG) participants will receive a 5-minute massage on the posterior deltoid area. Evaluations will be repeated three times before the applications, immediately after, and 30 minutes post-application and the effects of different applications will be compared through analysis.
PURPOSE: The study evaluates the use of heart rate variability (HRV), a measure of autonomic nervous system (ANS) modulation via wearable smart bands, to objectively assess cancer-related fatigue (CRF) levels. It aims to enhance understanding of fatigue by distinguishing between LF/HF ratios and LF/HF disorder ratios through HRV and photoplethysmography (PPG), identifying them as potential biomarkers.
METHODS: Seventy-one lung cancer patients and 75 non-cancer controls wore smart bands for one week. Fatigue was assessed using Brief Fatigue Inventory, alongside sleep quality and daily interference. HRV parameters were analyzed to compare groups.
RESULTS: Cancer patients showed higher fatigue and interference levels than controls (64.8% vs. 54.7%). Those with mild fatigue had elevated LF/HF disorder ratios during sleep (40% vs. 20%, P = 0.01), similar to those with moderate to severe fatigue (50% vs. 20%, P = 0.01), indicating more significant autonomic dysregulation. Notably, mild fatigue patients had higher mean LF/HF ratios than controls (1.9 ± 1.34 vs. 1.2 ± 0.6, P = 0.01), underscoring the potential of disorder ratios in signaling fatigue severity.
CONCLUSIONS: Utilizing wearable smart bands for HRV-based analysis is feasible for objectively assess CRF levels in cancer patients, especially during sleep. By distinguishing between LF/HF ratios and LF/HF disorder ratios, our findings suggest that wearable technology and detailed HRV analysis offer promising avenues for real-time fatigue monitoring. This approach has the potential to significantly improve cancer care by providing new methods for managing and intervening in CRF, particularly with a focus on autonomic dysregulation as a crucial factor.
First goal of the study is to phenotype patiens with hypergonadotropic ovarian dysfunction (WHO III) adequately. This group includes women with premature ovarian failure (POF), incipient ovarian failure (IOF), poor response after ovarian hyperstimulation, early menopause and hypergonadotropic primary amenorrhea. The standardized phenotyping consists of a questionnaire focusing on reproductive, medical, and family history; ultrasonography to assess ovarian reserve and/or antral follicle count and obtaining an extra blood sampling during routine endocrine screening for genotyping.

Phenotyping of patients presenting with ovarian dysfunction is of crucial importance when genotyping will be performed. The goal of this genotyping will be the identification of genetic factors associated with the (premature) depletion of the stock of ovarian follicles. It will be performed for isolated WHO III patients in an association (case-control) study for known candidate genes. In familial WHO III cases, genome wide linkage analysis will be performed.
Pediatric (12 to 23 months of age) participants received ProQuad® on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
PURPOSE:To provide a snore-preventing agent continuously releasing citral and/or geraniol and a snore-preventing tool comprising beddings, pajamas, etc., provided with the above snore-preventing agent. CONSTITUTION:The objective snore-preventing agent and snore-preventing tool continuously releases galenica and herb containing citral and geraniol, e.g. SHIN-I (bud of Magnolia fargesii), lemon grass and citronella, essential oil prepared therefrom or refined and separated citral and geraniol. It may be used in the form of a liquid or solid room aromatic, however, it is preferable to allow effective aspiration of the component by forming a concentrated atmosphere of the component near the nose and mouth. To attain the above state, it is preferable to directly attach the active component to beddings such as pillow, pillow cover and quilt cover or to clothings such as pajamas, nightcap and shirt. It is also effective for the elimination or mitigation of insomnia, shoulder discomfort, headache, nose stuffing, etc.
PURPOSE: To obtain such an effervescent mixture as somewhat slowly producing the finely dispersed or colloidal precipitates of a pharmaceutical active substance by the action of an acidic solution or a gastric acid. CONSTITUTION: This effervescent mixture contains at least one kind of alkaline salt or lysinate of insoluble or slightly soluble acidic drug. The alkali salt or lysinate is intimately mixed with the alkaline component of an effervescent system, and both the components may finely be ground and granulated with a binder. The surfaces of both the alkali salt or lysinate and the acidic component of the effervescent system are inactivated. Especially the effervescent mixture contains a surfactant, especially sodium dodecylsulfate, in an amount of at least 0.5 pt.wt., preferably 1-3 pts.wt., per 100 pts.wt. of the active substance, and/or a binder or suspension auxiliary, especially polyvinyl pyrrolidone, in an amount of at least 1 pt.wt., preferably 3-5 pts.wt.
Dispense ½ oz. (approx. 1 pump) of Pro-DenRx 2.0% Neutral Sodium Fluoride Solution into the provided mixing cup. Instruct patient to rinse vigorously for 30 seconds with ½ oz. of the solution around and between teeth, then expectorate. For maximum benefit repeat the rinse procedure with an additional ½ oz. of solution. Pro-DenRx 2.0% Neutral Sodium Fluoride Solution may also be applied full strength, with cotton pledgets, to teeth isolated with cotton rolls.
Posterior reversible encephalopathy syndrome (PRES) was reported in <0.5% of patients across clinical studies. The onset of symptoms occurred from 16 hours to 1 year after the first dose. PRES is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances. Mild to severe hypertension may be present. Magnetic resonance imaging is necessary to confirm the diagnosis of PRES.

Discontinue ZIRABEV in patients who develop PRES. Symptoms usually resolve or improve within days after discontinuing bevacizumab products, although some patients have experienced ongoing neurologic sequelae. The safety of reinitiating bevacizumab products in patients who developed PRES is not known.
The invention belongs to the medicine field, and specifically relates to a traditional Chinese medicine capsule and a preparation method of the same. To facilitate a capsule filling process, an inventor improves the granulation technique, and obtains spheroidic traditional Chinese medicine granules with a smooth and compact shape, good fluidity and a high bulk density. A raw material medicine can be either a single ingredient traditional Chinese medicine or a traditional Chinese medicine compound recipe. An extraction or decoction process can be performed with reference to the prior art. A main difference between the preparation method and the prior art is granulation. An extract is made into a dry extract and then soft materials are prepared, granules with a bulk density higher than 0.78g/cm3 are prepared. The preparation method of the invention can form spherical or spheroidic granules with the smooth and compact shape. The granules in a good shape are not easy to break into pieces and absorb moisture; the granules have good fluidity, are convenient to be filled in capsules and have a large crude drug loadability.